Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EGFRvIII-CAR-CD3/EGFR BiTE-transduced autologous T lymphocytes CARv3-TEAM-E

A preparation of autologous human T lymphocytes transduced with a CARv3-TEAM-E lentiviral vector encoding for an anti-epidermal growth factor receptor (EGFR) variant III (EGFRvIII) mutant chimeric T-cell receptor (chimeric antigen receptor or CAR) and a T-cell-engaging antibody molecule (TEAM) which comprises a bispecific T-cell engager (BiTE) against EGFR and the T-cell signaling domain CD3, with potential immunostimulatory and antineoplastic activities. Upon administration via Ommaya reservoir of the anti-EGFRvIII CAR-CD3/EGFR BiTE-transduced autologous T lymphocytes CARv3-TEAM-E, the lymphocytes bind to the EGFRvIII antigen on tumor cell surfaces and the BiTE binds to CD3 on bystander T cells; thereby killing EGFRvIII-expressing tumor cells through the administered CAR-T cells and wild-type (WT) EGFR-expressing tumor cells by bystander T cells, respectively. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types and absent in normal, healthy cells; it plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.
Synonym:autologous CARv3-TEAM-E-transduced T cells
autologous CARv3-TEAM-E-transduced T lymphocytes
Search NCI's Drug Dictionary